Early diagnostic value of survivin and its alternative splice variants in breast cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Khan, Salma ^a   Bennit, Heather F ^a   Turay, David ^a   Perez, Mia ^a   Mirshahidi, Saied ^a   Yuan, Yuan ^b   Wall, Nathan R ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Exosomes; Splice variants; Survivin

Indexed keywords

ANASTROZOLE; BIOLOGICAL MARKER; CARBOPLATIN; GEMCITABINE; INHIBITOR OF APOPTOSIS PROTEIN; PACLITAXEL; PROTEIN VARIANT; SURVIVIN; SURVIVIN 2B; SURVIVIN EX3; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULT; AGED; ALTERNATIVE RNA SPLICING; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER THERAPY; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC KIT; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SERUM; TUMOR BIOPSY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; APOPTOSIS; BREAST NEOPLASMS; EXOSOMES; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MIDDLE AGED; PROTEIN ISOFORMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899152371     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-176     Document Type: Article

References (27)

1. Sohn DM, Kim SY, Baek MJ, Lim CW, Lee MH, Cho MS, Kim TY. Expression of survivin and clinical correlation in patients with breast cancer. Biomed Pharmacother 2006, 60(6):289-292. 10.1016/j.biopha.2006.06.008, 16876381.
2. Al Dhaheri Y, Eid A, AbuQamar S, Attoub S, Khasawneh M, Aiche G, Hisaindee S, Iratni R. Mitotic arrest and apoptosis in breast cancer cells induced by Origanum majorana extract: upregulation of TNF-alpha and downregulation of survivin and mutant p53. PLoS One 2013, 8(2):e56649. 10.1371/journal.pone.0056649, 3579842, 23451065.
3. Rakha EA. Pitfalls in outcome prediction of breast cancer. J Clin Pathol 2013, 66(6):458-464. 10.1136/jclinpath-2012-201083, 23618694.
4. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin Ther Targets 2008, 12(4):463-476. 10.1517/14728222.12.4.463, 18348682.
5. van 't Veer LJDH, an de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536. 10.1038/415530a, 11823860.
6. Ryan B, O'Donovan N, Browne B, O'Shea C, Crown J, Hill AD, McDermott E, O'Higgins N, Duffy MJ. Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 2005, 92(1):120-124. 10.1038/sj.bjc.6602314, 2361728, 15611790.
7. Boidot R, Vegran F, Lizard-Nacol S. Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. Int J Mol Med 2009, 23(2):285-291.
8. Span PN, Tjan-Heijnen VC, Sweep FC. Is survivin expression nevertheless related to disease outcome in breast cancer?. Breast Cancer Res Treat 2007, 103(1):109. 10.1007/s10549-006-9350-5, 17028976.
9. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999, 59(24):6097-6102.
10. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, Altura RA. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005, 24(12):1994-2007. 10.1038/sj.onc.1208350, 15688031.
11. Koike H, Sekine Y, Kamiya M, Nakazato H, Suzuki K. Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. Urology 2008, 72(6):1229-1233. 10.1016/j.urology.2007.12.064, 18336887.
12. Khan S, Jutzy JMS, Aspe JR, McGregor DW, Neidigh JW, Wall NR. Survivin is released from cancer cells via exosomes. Apoptosis 2011, 16:1-12. 10.1007/s10495-010-0534-4, 3174681, 20717727.
13. Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One 2012, 7(10):e46737. 10.1371/journal.pone.0046737, 3473028, 23091600.
14. Khan S, Jutzy JMS, Aspe JR, Valenzuela MMA, Park J, Turay D, Wall NR. The application of membrane vesicles for cancer therapy. Book 3, Advances in Cancer Therapy, InTech Publishing 2011, 21-52. http://www.intechopen.com/articles/show/title/the-application-of-membrane-vesicles-for-cancer-therapy.
15. Savina A, Furlan M, Vidal M, Colombo MI. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem 2003, 278:20083-20090. 10.1074/jbc.M301642200, 12639953.
16. Khan S, Kumagai T, Vora J, Bose N, Sehgal I, Koeffler PH, Bose S. PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer 2004, 112(3):407-410. 10.1002/ijc.20447, 15382065.
17. Zeestraten EC, Benard A, Reimers MS, Schouten PC, Liefers GJ, van de Velde CJ, Kuppen PJ. The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry. Biomark Cancer 2013, 5:13-29. 3791955, 24179395.
18. Selemetjev S, Dencic TI, Marecko I, Jankovic J, Paunovic I, Savin S, Cvejic D. Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma. Pathol Res Pract 2013, 210(1):30-34.
19. Jeon C, Kim M, Kwak C, Kim HH, Ku JH. Prognostic role of survivin in bladder cancer: a systematic review and meta-analysis. PLoS One 2013, 8(10):e76719. 10.1371/journal.pone.0076719, 3799942, 24204662.
20. Vegran F, Mary R, Gibeaud A, Mirjolet C, Collin B, Oudot A, Charon-Barra C, Arnould L, Lizard-Nacol S, Boidot R. Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy. Cancer Res 2013, 73(17):5391-5401. 10.1158/0008-5472.CAN-13-0036, 23856250.
21. Marimpietri D, Petretto A, Raffaghello L, Pezzolo A, Gagliani C, Tacchetti C, Mauri P, Melioli G, Pistoia V. Proteome profiling of neuroblastoma-derived exosomes reveal the expression of proteins potentially involved in tumor progression. PLoS One 2013, 8(9):e75054. 10.1371/journal.pone.0075054, 3777909, 24069378.
22. O'Brien K, Rani S, Corcoran C, Wallace R, Hughes L, Friel AM, McDonnell S, Crown J, Radomski MW, O'Driscoll L. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer 2013, 49(8):1845-1859. 10.1016/j.ejca.2013.01.017, 23453937.
23. Islam A, Kageyama H, Hashizume K, Kaneko Y, Nakagawara A. Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-beta/2B. Med Pediatr Oncol 2000, 35(6):550-553. 10.1002/1096-911X(20001201)35:6<550::AID-MPO12>3.0.CO;2-Y, 11107115.
24. Ge QX, Li YY, Nie YQ, Zuo WG, Du YL. Expression of survivin and its four splice variants in colorectal cancer and its clinical significances. Med Oncol 2013, 30(2):535.
25. Moore AS, Alonzo TA, Gerbing RB, Lange BJ, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S. BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. Pediatr Blood Cancer 2013, 61(4):647-652.
26. Krieg A, Mahotka C, Krieg T, Grabsch H, Muller W, Takeno S, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 2002, 86(5):737-743. 10.1038/sj.bjc.6600153, 2375298, 11875736.
27. Meng H, Lu CD, Sun YL, Dai DJ, Lee SW, Tanigawa N. Expression level of wild-type survivin in gastric cancer is an independent predictor of survival. World J Gastroenterol 2004, 10(22):3245-3250.